Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Wbx Pharma Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct art unit and 1 distinct examiner. HAGHIGHATIAN, MINA is the examiner for this 1 pending action, which represents the company's total active prosecution at this time. The presence of only 1 pending office action in 1 distinct art unit points to a very specific technical focus for the company's current pharmaceutical filings. Practitioners should align their strategy with the standards of this 1 distinct art unit.
Since the company is working with 1 distinct examiner, HAGHIGHATIAN, MINA, the success of its current prosecution depends on this single individual's assessment. The involvement of 1 distinct art unit means the company is not currently dealing with the varied examination styles of multiple patent office divisions. Practitioners can dedicate their strategy to the specific requirements of this 1 distinct art unit and the 1 distinct examiner. This profile reflects a highly concentrated and limited prosecution effort for the company at this time. The interaction with HAGHIGHATIAN, MINA is the primary factor in the outcome of this 1 pending office action.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19088764 | INHALED HEDGEHOG INHIBITORS | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19088764 | INHALED HEDGEHOG INHIBITORS | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19088764 | INHALED HEDGEHOG INHIBITORS | HAGHIGHATIAN, MINA | 1616 | §103§112 | Non-Final OA | — | Pending | Mar 24, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWbx Pharma Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mina Haghighatian has the most, with 1 of Wbx Pharma Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
